Meta-Analysis of the Reversible Inhibitors of Monoamine Oxidase Type A Moclobemide and Brofaromine for the Treatment of Depression

@article{LotufoNeto1999MetaAnalysisOT,
  title={Meta-Analysis of the Reversible Inhibitors of Monoamine Oxidase Type A Moclobemide and Brofaromine for the Treatment of Depression},
  author={Francisco Lotufo-Neto and Madhukar H. Trivedi and Michael E. Thase},
  journal={Neuropsychopharmacology},
  year={1999},
  volume={20},
  pages={226-247}
}
The reversible inhibitors of monoamine oxidase type A (RIMAs) are a newer group of antidepressants that have had much less impact on clinical psychopharmacology than another contemporary class of medications, the selective serotonin reuptake-inhibitors (SSRIs). The RIMAs agents are distinguished from the older monoamine oxidase inhibitors (MAOIs) by their selectivity and reversibility. As a result, dietary restrictions are not required during RIMA therapy, and hypertensive crises are quite rare… Expand
Moclobemide: therapeutic use and clinical studies.
  • U. Bonnet
  • Psychology, Medicine
  • CNS drug reviews
  • 2003
Moclobemide is a reversible inhibitor of monoamine-oxidase-A (RIMA) and has been extensively evaluated in the treatment of a wide spectrum of depressive disorders and less extensively studied inExpand
Opportunities for reversible inhibitors of monoamine oxidase-A (RIMAs) in the treatment of depression
TLDR
Recent progress in RIMAs toward the treatment of treatment-resistant depression is discussed, with the new class of reversible monoamine oxidase inhibitors (RIMAs) having shown efficacy in depression, with safety and tolerability comparable to SSRIs. Expand
Current Place of Monoamine Oxidase Inhibitors in the Treatment of Depression
This paper reviews the discovery and history of the use of irreversible monoamine oxidase (MAO) inhibitors (MAOIs) such as phenelzine, tranylcypromine and isocarboxazid, as well as the secondExpand
Monoamine Oxidase Inhibitors: A Modern Guide to an Unrequited Class of Antidepressants
TLDR
The mechanisms of therapeutic action of MAOIs are discussed, but also the mechanisms explaining their side effects, including hypertensive interactions with dietary tyramine (so-called "cheese reactions") and drug interactions that can lead to hypertensive reactions with some drugs and serotonin toxicities with others. Expand
Reversible Inhibitors of Monoamine Oxidase-A (RIMAs): Robust, Reversible Inhibition of Human Brain MAO-A by CX157
TLDR
CX157 is the first agent in the RIMA class with documented reversible inhibition of human brain MAO-A, supporting its classification as a R IMA, and the first RIM a with observed plasma levels that can serve as a biomarker for the degree of brain MAo-A inhibition. Expand
Transdermal Selegiline: The New Generation of Monoamine Oxidase Inhibitors
TLDR
Clinicians should familiarize themselves with the properties and indications for the new generation of MAOIs and it is possible that STS may demonstrate benefit in MDD with atypical features or MDD resistant to other antidepressants. Expand
Novel transdermal delivery formulation of the monoamine oxidase inhibitor selegiline nearing release for treatment of depression.
  • M. Thase
  • Psychology, Medicine
  • The Journal of clinical psychiatry
  • 2006
TLDR
The holy grail of this search for a better MAOI has been identification of a drug that did not require a special diet, has a tolerability and ease-of-use profile comparable to the selective serotonin reuptake inhibitors (SSRIs), and is as effective as tranylcypromine or phenelzine. Expand
Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: focus on modulation of CNS monoamine neurotransmitter release.
TLDR
The latest advances in understanding the way in which MAO inhibitors affect the release of the monoamine neurotransmitters dopamine, noradrenaline and serotonin in the CNS are described, with an accent on the importance of these effects for the clinical actions of the drugs. Expand
Selegiline transdermal system: a novel treatment option for major depressive disorder
TLDR
Selegiline transdermal system is safe and effective in treating major depressive disorder at the dose range of 6 – 12 mg/ 24 h, without the need for dietary precautions at the 6 mg/24 h dose. Expand
Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology
TLDR
The clinical potential of MAO inhibitors together with detailed knowledge of the enzyme's binding site structure should lead to future developments with these drugs. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 127 REFERENCES
Newer and Older Monoamine Oxidase Inhibitors
SummaryMonoamine oxidase (MAO) inhibitors (MAOIs) available at present can be classified into 3 types: (i) older, irreversible nonselective (first generation) agents such as phenelzine,Expand
The advent of a new generation of monoamine oxidase inhibitor antidepressants: pharmacologic studies with moclobemide and brofaromine.
TLDR
Using a rat renal nerve preparation, it is demonstrated that acute administration of either moclobemide or brofaromine does not cause a decrease in blood pressure or a significant reduction in sympathetic renal nerve activity, compared with those obtained with clorgyline or desipramine. Expand
Tolerability of moclobemide, a new reversible inhibitor of monoamine oxidase‐A, compared with other antidepressants and placebo
TLDR
It is concluded that moclobemide may be the second‐generation antidepressant doctors were waiting for, equally effective as the classical antidepressants but far better tolerated. Expand
Clinical efficacy of reversible and selective inhibitors of monoamine oxidase A in major depression
  • E. Paykel
  • Psychology, Medicine
  • Acta psychiatrica Scandinavica. Supplementum
  • 1995
TLDR
The evidence indicates that moclobemide is effective in typical severe depression with melancholia rather than being limited to less lypical subtypes. Expand
A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl. A selective monoamine oxidase inhibitor.
TLDR
It was concluded that (-)-deprenyl is an effective antidepressant in a dose range where it is distinguished by the absence of many of the side effects typical of nonselective MAO inhibitors. Expand
Double-blind comparison of moclobemide and tranylcypromine in depression.
TLDR
Both treatments resulted in significant amelioration of depression as determined by all rating instruments, and the tolerability of both drugs was good, although moclobemide appeared to possess a small advantage in this regard. Expand
Efficacy of a reversible monoamine oxidase‐A inhibitor versus imipramine in subgroups of depressed patients
TLDR
The conclusion from the 2 studies is that, contrary to what is frequently stated for monoamine oxidase inhibitors, moclobemide appears as effective as a tricylic in treating endogenous depression. Expand
Reversible and selective inhibitors of monoamine oxidase A in the treatment of depressed elderly patients
TLDR
Clinical studies show that, in elderly depressed patients, moclobemide is at least as effective as other antidepressants, and is as well tolerated in elderly people as in younger people. Expand
Efficacy of reversible inhibitors of monoamine oxidase‐A in various forms of depression
TLDR
The design and the main therapeutic results of 3 controlled double‐blind studies comparing moclobemide with tricyclics and/or placebo in depressed patients are presented and it is shown that reversible inhibitors of MAO‐A demonstrate good efficacy independently of the diagnostic category of depression. Expand
Monoamine Oxidase Inhibitors Phenelzine and Brofaromine Increase Plasma Serotonin and Decrease 5‐Hydroxyindoleacetic Acid in Patients with Major Depression: Relationship to Clinical Improvement
TLDR
The consistent relationship the authors found between the biochemical and clinical changes again suggests and supports a key role of 5-HT in the antidepressant effect of these MAO inhibitors. Expand
...
1
2
3
4
5
...